Epigenomics, Myriad to Hunt DNA Methylation Markers for Cancer Drug Response | GenomeWeb

Epigenomics, Myriad to Hunt DNA Methylation Markers for Cancer Drug Response

May 09, 2007

NEW YORK (GenomeWeb News) - Epigenomics today said it will collaborate with Myriad Genetics to identify DNA methylation biomarkers that may predict patient response to a cancer drug.

Under the collaboration, Epigenomics will use its Differential Methylation Hybridization microarray platform for genome-wide profiling of samples provided by Myriad. The company hopes to discover methylation biomarkers that are linked to sensitivity and resistance to the undisclosed marketed oncology drug.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Breaking News

The Scan

Security Policy Change at FDA

ScienceInsider reports that a new security policy at the US Food and Drug Administration may prevent foreign nationals from working there.

Fancier than the 'Sit and Reach'

WBUR in Boston looks into Orig3n's genetic fitness assessments to find more research is needed.

Collected and Stored

Cleveland.com reports that getting a DNA profile removed from a law enforcement database can be tricky.

This Week in PNAS

In PNAS this week: de novo mutations contribute to non-syndromic craniosynostosis, fungal tree of life, and more.

Featured White Papers

Compatibility of CYTAG CGH Labeling Kit with Illumina 24sure Microarrays

Optimized NGS Library Preparation with Acoustic Liquid Handling